Top 50 Cell Line Development in Europe

Cytena develops single-cell printing technology and automated solutions for cell line development, enabling the efficient production of stable cell lines for therapeutic applications. Their systems streamline workflows for biopharmaceutical companies, reducing the time and cost associated with developing biologics while ensuring compliance with regulatory standards.

Alvotech specializes in the development and manufacturing of biosimilars through a vertically integrated process that includes cell line development and fill-finish manufacturing. This approach enhances access to affordable biologic medicines, addressing the high costs associated with traditional biologic therapies.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

SIMABS NV has developed a continuous bioprocessing platform for the rapid and cost-effective development and GMP manufacturing of monoclonal and bispecific antibodies, addressing the need for high-quality biologics in personalized medicine. Their integrated approach offers a complete solution, including cell line development and regulatory support, enabling biopharmaceutical companies to accelerate their product development timelines while reducing costs.

The startup develops a DNA integration platform that enhances the engineering of cell lines for gene and cell therapies, specifically targeting the production of recombinant adeno-associated virus vectors. By improving viral vector yield and efficacy, the company enables biopharmaceutical firms to produce more effective therapies for serious diseases.

Mytos is developing a fully automated platform for the manufacture of any human cell type, utilizing advanced robotics and software to streamline cell culture processes. This technology addresses the challenges of contamination and human error in cell production, enabling consistent, high-quality output at a scale that allows one technician to achieve the productivity of ten scientists working manually.

PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.

Roslin Technologies develops pluripotent animal stem cells for the cultivated meat industry, providing scalable cell lines that can differentiate into muscle and fat tissues. This technology addresses the growing global demand for sustainable protein by enabling the production of real meat without raising animals, thereby reducing environmental impact and improving animal welfare.

Scarlet Therapeutics develops a proprietary platform that generates therapeutic red blood cells (tRBCs) containing high levels of therapeutic proteins, enabling targeted treatment for diseases such as hyperammonemia, hyperoxaluria, cancer, and autoimmune disorders. By utilizing cell lines for production instead of donated stem cells, the company addresses manufacturing challenges and enhances the efficacy of red blood cell-based therapies.

Antiverse utilizes machine learning and advanced cell line engineering to design target-specific antibody libraries for challenging drug targets, including G-protein coupled receptors and ion channels. The platform accelerates the antibody discovery process, enabling the development of functional therapeutics within six months, addressing the lengthy timelines typically associated with traditional drug development methods.

The startup has developed a fluid-shaping technology that replaces traditional microtiter plates with a microscale system for single-cell cloning, allowing researchers to expose cells to relevant experimental conditions. This technology enables multiple users to conduct simultaneous experiments efficiently, addressing the limitations of current cloning methods.

Astraveus is developing the Lakhesys - The Benchtop Cell Factory™, a microfluidics-powered platform that integrates hardware, software, and consumables for cell and gene therapy manufacturing. This solution enhances development throughput by up to 100 times while reducing resource consumption by 10 to 20 times, making cell therapies more accessible to patients.

Cellino is developing a scalable, automated biomanufacturing system that produces personalized cell therapies using patient-derived cells. This technology addresses the challenges of high costs and lengthy production times in delivering potentially curative treatments for individual patients.

The startup develops a gene editing and genome engineering platform that creates human-compatible organ tissue cells for solid organ and therapeutic cell transplantation. This technology aims to improve outcomes for patients with life-threatening diseases by enabling successful kidney and islet cell transplants.

Turbine's Simulated Cell™ platform utilizes AI to predict biological responses by simulating experiments across various models, including engineered cell lines and patient samples. This technology accelerates drug development by generating actionable insights in half the time of traditional methods, enabling researchers to identify optimal experimental pathways for novel cancer therapies.

Arsenale BioYards is a bio-manufacturing platform that combines hardware and software to facilitate the design and cultivation of engineered cells for product creation. This technology enables a shift from resource extraction to sustainable cellular farming, addressing the need for a more efficient and environmentally friendly bioeconomy.

GentiBio develops a modular engineering platform that produces stable, optimized T regulatory cells (Tregs) with specific IL-2 signaling for the treatment of autoimmune and inflammatory diseases. This technology addresses the limitations of existing Treg therapeutics by enabling scalable manufacturing and targeted delivery, enhancing efficacy and safety for patients.

The startup develops machine-learning tools to design cell factories capable of producing a wide range of products, including food, fabrics, and medicines. By simplifying the complex process of cellular manufacturing, the company aims to replace traditional farms and factories, promoting a more sustainable production model.

The startup operates a cell therapy research and manufacturing platform that enhances process control and scalability in autologous cell and gene therapy bioprocessing. By enabling parallel execution of cell culture conditions, the platform reduces manufacturing costs while improving efficiency in process development.

CellRev specializes in process intensification for cell manufacturing through advanced bioprocessing techniques that enhance yield and efficiency. The company reduces high production costs and lengthy timelines in biomanufacturing, facilitating faster and more cost-effective development of cell-based therapies.

TreeFrog Therapeutics develops proprietary C-Stem™ technology to produce scalable, high-quality cell therapies, including a lead program targeting Parkinson’s disease. The company addresses the need for effective and safe regenerative medicine by enabling the production of billions of cells in a single batch, facilitating clinical trials and patient access.

The startup develops a machine platform that integrates silicon chip technology with microfluidic processing for the large-scale manufacturing of personalized cell therapies. This technology enables real-time control and manipulation of cellular processes, providing cost-effective and safe treatments tailored for individual cancer patients.

The startup provides contract development services for preclinical and clinical drug projects, specializing in the supply of ready-to-inject adipose-derived allogeneic stem cells. This offering enables healthcare companies to lower manufacturing costs and improve the affordability of cell therapies.

Newcells Biotech specializes in developing induced pluripotent stem cell-derived in vitro models for drug discovery, focusing on human tissue simulations such as retinal, kidney, and lung models. Their services provide critical data on drug efficacy and safety, enhancing the predictive accuracy of pre-clinical studies and facilitating clinical translation.

Sensible Biotechnologies develops a cell-based platform for the production of non-immunogenic, pure, and highly functional mRNA therapeutics and vaccines, addressing the limitations of traditional mRNA manufacturing methods. By establishing a novel biomanufacturing infrastructure, the company aims to enhance global biosecurity and improve the efficiency of mRNA medicine development.

The startup develops bacterial protein polymers that deliver bioactive cues essential for cell growth and division, specifically for cultivated meat and cell therapy manufacturing. This technology provides a cost-effective and multifunctional material that meets the needs of biomedical research and therapy markets at an industrial scale.

Thymmune Therapeutics is developing a machine learning platform for thymic cell engineering to enhance the generation and function of thymic-derived T-cells. This technology aims to improve the efficacy and precision of T-cell therapies for cancer and autoimmune diseases by optimizing immune cell treatments.

Cellular Origins develops the Constellation robotic automation platform for the scalable manufacturing of cell and gene therapies, integrating production equipment to enhance efficiency. This technology reduces labor by 16 times, cuts costs by 51%, and enables closed, data-rich production processes to meet the growing demand for cell therapies.

Cellcolabs specializes in the industrial-scale, GMP production of high-quality mesenchymal stromal cells (MSCs) for research and clinical applications. By providing these cells, the company aims to enhance the availability and affordability of MSCs, facilitating advancements in treatments for severe and incurable diseases.

Ori Biotech has developed the IRO® platform, a fully automated and standardized manufacturing system for cell and gene therapies that enhances biological performance while minimizing batch failures and reducing costs. This technology addresses the challenges of high manufacturing costs and low throughput, enabling scalable production and wider patient access to lifesaving treatments.

Unicorn Biotechnologies develops bio-reactors that standardize, digitize, and automate cell culture workflows, enabling efficient scaling from pilot to commercial manufacturing. Their technology addresses the challenges of batch failures and high costs in cell-based production, allowing researchers to focus on experimental design and analysis.

Genewity B.V. develops autologous thymus tissue using gene-modified induced pluripotent stem cells to restore immune function in patients with congenital athymia and autoimmune disorders. This technology addresses the lack of effective treatments for severe immune deficiencies by creating patient-specific thymic organoids that enhance T-cell development and immune tolerance.

Cell4Food develops cellular agriculture technologies to produce cell-based seafood products, including fish, molluscs, and crustaceans, using non-invasive biopsies and bioreactor cell expansion. This approach addresses the environmental impact of traditional aquaculture by offering sustainable, ethical, and scalable alternatives with reduced resource consumption and minimized contamination risks.

This biotechnology startup specializes in the development and commercial production of cultivated fish using cellular agriculture techniques to create seafood products from fish cells. By providing nutritious fish alternatives, the company addresses the environmental impact of traditional fishing practices and promotes sustainable food sources without harming marine ecosystems.

Limula provides a modular, automated platform that integrates a bioreactor and centrifuge for the on-demand, at-scale manufacturing of cell therapies. This technology addresses the high costs and complexity of producing personalized cell therapies, enabling efficient processing of various cell types in a single device.

Provides a fully synthetic, customizable peptide hydrogel platform for 3D cell culture, enabling researchers to model human development and disease without using animals or animal-derived products. This system improves reproducibility and reliability in in vitro studies, supporting a wide range of endpoint experiments with optically transparent, ready-to-use hydrogels.

Extracellular is a contract development and manufacturing organization (CDMO) that specializes in biomanufacturing processes for cultivated meat and seafood, utilizing non-human cell culture technologies to produce biomass efficiently. The company addresses the challenge of scaling production in sustainable biotechnology by providing tailored cell culture media and large-scale bioreactor capabilities to accelerate time to market for its clients.

Flash Therapeutics specializes in the development of gene and cell-based therapies using its proprietary lentiviral vector platform, which enables stable and long-term DNA transfer. The company provides reliable viral vector manufacturing services to meet the growing demand for effective treatments in cell and gene therapy.

Cimeio Therapeutics develops gene-editing technologies that create shielded hematopoietic stem cells (HSCs) to protect healthy cells during immunotherapy for leukemic tumors and autoimmune diseases. This approach enhances the safety and efficacy of hematopoietic stem cell transplants and adoptive cell therapies by preventing depletion of healthy cells while targeting diseased ones.

Mogrify develops in vivo reprogramming therapies that utilize a proprietary platform to identify key transcriptomic and epigenetic factors necessary for direct cellular conversion. This technology aims to restore lost cell types in patients with degenerative diseases, particularly in otology, ophthalmology, and diabetes, addressing significant unmet clinical needs.

2seventy bio develops immuno-oncology cell therapies that utilize engineered T cells to target and eliminate cancer cells. The company aims to extend patients' lives by providing effective treatment options that address the limitations of current cancer therapies.

Multus develops animal-free growth media formulations for cellular agriculture, utilizing data science and high-throughput automation to create scalable, cost-effective solutions. Their products replace traditional fetal bovine serum with serum-free alternatives, enabling cultivated meat companies to reduce input costs and enhance bioprocess performance.

PL BioScience provides human Platelet Lysate-based 2D and 3D cell culture solutions that serve as a xeno-free alternative to Fetal Bovine Serum, addressing the need for safer and more effective growth environments in research and clinical applications. Their ELAREM™ platform offers various grades of human Platelet Lysate, ensuring compliance with safety standards for diverse applications in regenerative medicine and cellular therapeutics.

EV Biotech develops microbial cell factories that utilize synthetic biology techniques for the industrial production of chemicals and proteins. This approach addresses the need for sustainable and efficient manufacturing processes in the chemical and biotechnology sectors.

Coding Bio develops a high-throughput cell discovery platform that utilizes machine learning to screen millions of modular protein candidates for effective cancer immunotherapies. This approach accelerates the identification of optimal therapies, reducing development time and increasing the likelihood of clinical success for patients.

The startup develops AI-driven live-cell imaging technology to predict and optimize stem cell differentiation, enabling the scalable manufacture of any cell or tissue in the body. This approach addresses the need for effective stem cell-based therapies for chronic diseases, facilitating data-driven drug development and improving patient outcomes.

Yuri manufactures hardware for the aviation and aerospace industry, specializing in microgravity research applications that enable the growth of complex 3D cell cultures and the analysis of biomolecular structures. By utilizing the unique conditions of space, Yuri enhances drug development and cell-based therapies, addressing limitations in terrestrial research environments.

HemostOD engineers and manufactures universal platelets from a stable megakaryocytic cell line using advanced microfluidic technologies, providing a scalable and rapid source of high-quality platelets. This technology addresses the need for effective treatments in patients with thrombocytopenia and facilitates targeted delivery of therapeutic agents in regenerative medicine applications.

CryoLogyx develops cryopreserved, assay-ready cells that are directly adhered to microplates, enabling experiments to commence just 24 hours post-thaw. This technology enhances the precision and efficiency of cell-based research, significantly reducing the time and resources required for routine cell culture.

Mo:re is developing a robotic and software platform that automates 3D cell culture processes for medical research, enhancing traceability and reproducibility in experiments. This technology enables researchers to conduct drug development and screening more efficiently, reducing time and costs associated with traditional methods.